Subtitle: ADMET & Pharmacogenomic Research Tools for Drug Metabolism Studies.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for UGT1A6-mediated metabolism screening and pharmacogenomic drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Enzyme | UGT1A6 Recombinant Protein (Wild Type & UGT1A6*2 Mutant) High purity (>95%), Endotoxin <1EU/ug. Catalytic domain (AA 27-295), HEK293 expressed, Sequence Verified. |
View UGT1A6 Products |
| Gene Delivery | UGT1A6 Promise-ORF / Lentivirus Full-length ORF with ER retention signal for stable cell line construction (native ER expression). |
View UGT1A6 Products |
| Benchmark Ab | Anti-UGT1A6 Antibody (Polyclonal / Recombinant) For Western blot, ELISA, and expression profiling. |
View UGT1A6 Products |
| Validator | UGT1A6 siRNA Set For knockdown verification and specificity control in metabolic assays. |
View UGT1A6 Products |
| Related Target A | UGT1A1 Major Phase II metabolic partner for bilirubin glucuronidation; key for DDI studies and irinotecan toxicity. |
View UGT1A1 Products |
| Related Target B | CYP3A4 Key Phase I enzyme for integrated ADME/Tox pathway assessment. |
View CYP3A4 Products |
| Related Target C | UGT1A9 Drug glucuronidation enzyme; frequently co-screened with UGT1A6 for metabolic profiling. |
View UGT1A9 Products |
Critical Assay Challenges & Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Localization (ER) | Lentivirus systems for stable cell line generation ensuring native conformation |
| Polymorphism Profiling | Sequence Verified ORFs covering major UGT1A6 wild-type and allelic variants (e.g., UGT1A6*2 T181A+R184S) |
| Lack of Expression Controls | Sequence-verified Recombinant positive control antibodies included |
| Off-Target Metabolic Interference | Validated siRNA included for specificity and knock-out baseline checks |
| Isoform-Selective Inhibition Screening | UGT1A6-specific antigen with <95% homology to other UGT1A isoforms; mass spec verified identity |
| Enzyme Kinetics Standardization | High purity (>95%) for consistent Vmax/Km determination with serotonin or acetaminophen substrates |
Live UGT1A6 R&D Tracker
Market data changes daily. Access the latest global research status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Pharmacogenomics Research
- ➤ Drug Metabolism Studies
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The role of UGT1A6 in the global R&D landscape is rapidly evolving from a standard ADME/Tox liability target to a critical component of personalized medicine. As a major Phase II metabolizing enzyme responsible for the glucuronidation of planar phenols and various therapeutic drugs (such as acetaminophen and serotonin), understanding UGT1A6 activity is essential for predicting drug clearance and toxicity. Current research focuses on inter-individual variability caused by pharmacogenomic polymorphisms (e.g., UGT1A6*2, *3, *4). As precision medicine advances, UGT1A6 genotyping is becoming integral to predicting adverse drug reactions and optimizing therapeutic efficacy through personalized dosing strategies. The next wave of R&D is heavily focused on evaluating drug-drug interactions (DDIs) and designing prodrugs that leverage specific UGT enzyme profiles.
Research Modalities & Applications
| Research Area | Key Application | Critical Assay Need (Why TarMart?) |
|---|---|---|
| Small Molecule (NCEs) | Clearance and DDI screening | Need native UGT1A6 via Lentivirus cell lines for accurate metabolic profiling |
| Prodrugs | Targeted delivery activation | Need sequence-verified UGT1A6 expression (wild-type and variant) to assess activation kinetics |
| Pharmacogenomics | Variant impact on drug metabolism | Need precise mutant/allele ORFs (e.g., UGT1A6*2) for comparative activity assays |
| ADMET / DMPK | Drug-Drug Interaction Screening | Isoform-selective inhibition assays requiring purified UGT1A6 vs UGT1A1/1A9 |